Michael T Lotze

List of Publications by Year
in descending order

206 papers	35,809 citations	7561 77 h-index	3482 182 g-index
209 all docs	209 docs citations	209 times ranked	47323 citing authors

#	Article	IF	Citations
1	Sequestsome-1/p62-targeted small molecules for pancreatic cancer therapy. Drug Discovery Today, 2022, 27, 362-370.	3.2	6
2	Intrapleural interleukin-2â€“expressing oncolytic virotherapy enhances acute antitumor effects and T-cell receptor diversity in malignant pleural disease. Journal of Thoracic and Cardiovascular Surgery, 2022, 163, e313-e328.	0.4	13
3	AllergoOncology: Danger signals in allergology and oncology: AÂEuropean Academy of Allergy and Clinical Immunology (EAACI) Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2594-2617.	2.7	5
4	Gut microbiota composition and outcomes following neoadjuvant therapy in patients with localized pancreatic cancer: A prospective biomarker study.. Journal of Clinical Oncology, 2022, 40, 4143-4143.	0.8	1
5	Oncolytic virus promotes tumor-reactive infiltrating lymphocytes for adoptive cell therapy. Cancer Gene Therapy, 2021, 28, 98-111.	2.2	30
6	CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer. Gut, 2021, 70, 890-899.	6.1	59
7	Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation in Localized Pancreatic Cancer: A Caseâ€“Control Matched Analysis. Annals of Surgical Oncology, 2021, 28, 3779-3788.	0.7	12
8	In Vivo Priming of Peritoneal Tumor-Reactive Lymphocytes With a Potent Oncolytic Virus for Adoptive Cell Therapy. Frontiers in Immunology, 2021, 12, 610042.	2.2	6
9	Fighting Fire With Fire: Oncolytic Virotherapy for Thoracic Malignancies. Annals of Surgical Oncology, 2021, 28, 2715-2727.	0.7	11
10	ASO Author Reflection: Viruses, the Lung, and Thoracic Neoplasms: Breaking Bad. Annals of Surgical Oncology, 2021, 28, 2728-2729.	0.7	0
11	Impact of G-CSF during neoadjuvant therapy on outcomes of operable pancreatic cancer.. Journal of Clinical Oncology, 2021, 39, 4126-4126.	0.8	1
12	SMAD4 loss is associated with response to neoadjuvant chemotherapy plus hydroxychloroquine in patients with pancreatic adenocarcinoma. Clinical and Translational Science, 2021, 14, 1822-1829.	1.5	12
13	Intratumoral T cell clonality and survival in a randomized phase II study of preoperative autophagy inhibition in combination with gemcitabine and nab-paclitaxel treatment in patients with resectable pancreatic cancer.. Journal of Clinical Oncology, 2021, 39, e16001-e16001.	0.8	3
14	Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Cancer Medicine, 2021, 10, 5041-5050.	1.3	35
15	Encouraging longâ€term survival following autophagy inhibition using neoadjuvant hydroxychloroquine and gemcitabine for highâ€risk patients with resectable pancreatic carcinoma. Cancer Medicine, 2021, 10, 7233-7241.	1.3	12
16	Experimental respiratory exposure to putative Gulf War toxins promotes persistent alveolar macrophage recruitment and pulmonary inflammation. Life Sciences, 2021, 282, 119839.	2.0	3
17	Gutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer. Journal of Immunotherapy, 2021, 44, 49-62.	1.2	7
18	Serum IL27 in Relation to Risk of Hepatocellular Carcinoma in Two Nested Caseâ€“Control Studies. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 388-395.	1.1	8

#	Article	IF	Citations
19	680â€…Isoforms of neuropilin-2 regulate distinct macrophage functions and are associated with unique tumor-associated macrophages in murine and human breast cancer. , 2021, 9, A708-A708.		0
20	Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma. American Journal of Roentgenology, 2020, 214, 362-369.	1.0	28
21	Prognostic Value of the Systemic Immune-Inflammation Index (SII) After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer. Annals of Surgical Oncology, 2020, 27, 898-906.	0.7	51
22	HMGB1 Promotes Myeloid Egress and Limits Lymphatic Clearance of Malignant Pleural Effusions. Frontiers in Immunology, 2020, 11, 2027.	2.2	4
23	Bi- and Tri-Specific T Cell Engager-Armed Oncolytic Viruses: Next-Generation Cancer Immunotherapy. Biomedicines, 2020, 8, 204.	1.4	41
24	Defining best practices for tissue procurement in immuno-oncology clinical trials: consensus statement from the Society for Immunotherapy of Cancer Surgery Committee. , 2020, 8, e001583.		15
25	Autophagy inhibition is the next step in the treatment of glioblastoma patients following the Stupp era. Cancer Gene Therapy, 2020, 28, 971-983.	2.2	6
26	Characteristics of Malignant Pleural Effusion Resident CD8+ T Cells from a Heterogeneous Collection of Tumors. International Journal of Molecular Sciences, 2020, 21, 6178.	1.8	9
27	Actin-binding protein profilin1 promotes aggressiveness of clear-cell renal cell carcinoma cells. Journal of Biological Chemistry, 2020, 295, 15636-15649.	1.6	18
28	Longitudinal Analysis of T and B Cell Receptor Repertoire Transcripts Reveal Dynamic Immune Response in COVID-19 Patients. Frontiers in Immunology, 2020, 11, 582010.	2.2	56
29	The Unknown Unknowns: Recovering Gamma-Delta T Cells for Control of Human Immunodeficiency Virus (HIV). Viruses, 2020, 12, 1455.	1.5	3
30	HMGB1 as a potential biomarker and therapeutic target for severe COVID-19. Heliyon, 2020, 6, e05672.	1.4	118
31	DC/Lâ€SIGNs of hope in the COVIDâ€19 pandemic. Journal of Medical Virology, 2020, 92, 1396-1398.	2.5	39
32	Ratcheting down the virulence of SARSâ€CoVâ€2 in the COVIDâ€19 pandemic. Journal of Medical Virology, 2020, 92, 2379-2380.	2.5	7
33	A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine/Nab-Paclitaxel in Pancreatic Cancer Patients. Clinical Cancer Research, 2020, 26, 3126-3134.	3.2	133
34	Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection. Journal of Translational Medicine, 2020, 18, 261.	1.8	32
35	The Multifaceted Effects of Autophagy on the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1225, 99-114.	0.8	18
36	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610

#	Article	IF	Citations
37	Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19. , 2020, 8, e000878.		63
38	The Adaptome as Biomarker for Assessing Cancer Immunity and Immunotherapy. Methods in Molecular Biology, 2020, 2055, 369-397.	0.4	17
39	Outcomes and efficacy of neoadjuvant chemoradiation versus chemotherapy in localized pancreatic cancer.. Journal of Clinical Oncology, 2020, 38, 727-727.	0.8	1
40	Johnny on the Spot-Chronic Inflammation Is Driven by HMGB1. Frontiers in Immunology, 2019, 10, 1561.	2.2	45
41	DNA released from neutrophil extracellular traps (NETs) activates pancreatic stellate cells and enhances pancreatic tumor growth. OncoImmunology, 2019, 8, e1605822.	2.1	77
42	Clockophagy is a novel selective autophagy process favoring ferroptosis. Science Advances, 2019, 5, eaaw2238.	4.7	286
43	A peaceful death orchestrates immune balance in a chaotic environment. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 22901-22903.	3.3	7
44	Prolactin Promotes Fibrosis and Pancreatic Cancer Progression. Cancer Research, 2019, 79, 5316-5327.	0.4	36
45	Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis. Annals of Oncology, 2019, 30, 1902-1913.	0.6	144
46	Making cold malignant pleural effusions hot: driving novel immunotherapies. OncoImmunology, 2019, 8, e1554969.	2.1	46
47	Enhanced Neutrophil Extracellular Trap Formation in Acute Pancreatitis Contributes to Disease Severity and Is Reduced by Chloroquine. Frontiers in Immunology, 2019, 10, 28.	2.2	68
48	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.		64
49	The platelet NLRP3 inflammasome is upregulated in a murine model of pancreatic cancer and promotes platelet aggregation and tumor growth. Annals of Hematology, 2019, 98, 1603-1610.	0.8	19
50	Serum and nutrient deprivation increase autophagic flux in intervertebral disc annulus fibrosus cells: an in vitro experimental study. European Spine Journal, 2019, 28, 993-1004.	1.0	28
51	Different measures of HMGB1 location in cancer immunology. Methods in Enzymology, 2019, 629, 195-217.	0.4	11
52	Inhibiting Autophagy in Renal Cell Cancer and the Associated Tumor Endothelium. Cancer Journal (Sudbury, Mass), 2019, 25, 165-177.	1.0	5
53	TLR4-dependent upregulation of the platelet NLRP3 inflammasome promotes platelet aggregation in a murine model of hindlimb ischemia. Biochemical and Biophysical Research Communications, 2019, 508, 614-619.	1.0	25
54	JTC801 Induces pH-dependent Death Specifically in Cancer Cells and Slows Growth of Tumors in Mice. Gastroenterology, 2018, 154, 1480-1493.	0.6	105

#	Article	IF	Citations
55	Extracellular DNA promotes colorectal tumor cell survival after cytotoxic chemotherapy. Journal of Surgical Research, 2018, 226, 181-191.	0.8	29
56	High mobility group protein B1 controls liver cancer initiation through yesâ€associated protein â€dependent aerobic glycolysis. Hepatology, 2018, 67, 1823-1841.	3.6	88
57	AMPK-Mediated BECN1 Phosphorylation Promotes Ferroptosis by Directly Blocking System Xcâ€" Activity. Current Biology, 2018, 28, 2388-2399.e5.	1.8	471
58	Chloroquine reduces hypercoagulability in pancreatic cancer through inhibition of neutrophil extracellular traps. BMC Cancer, 2018, 18, 678.	1.1	133
59	PINK1 and PARK2 Suppress Pancreatic Tumorigenesis through Control of Mitochondrial Iron-Mediated Immunometabolism. Developmental Cell, 2018, 46, 441-455.e8.	3.1	176
60	RAGE-specific single chain Fv for PET imaging of pancreatic cancer. PLoS ONE, 2018, 13, e0192821.	1.1	7
61	Adoptive transfer of natural killer cells promotes the anti-tumor efficacy of T cells. Clinical Immunology, 2017, 177, 76-86.	1.4	12
62	HSPA5 Regulates Ferroptotic Cell Death in Cancer Cells. Cancer Research, 2017, 77, 2064-2077.	0.4	353
63	A Tumor Cell-Selective Inhibitor of Mitogen-Activated Protein Kinase Phosphatases Sensitizes Breast Cancer Cells to Lymphokine-Activated Killer Cell Activity. Journal of Pharmacology and Experimental Therapeutics, 2017, 361, 39-50.	1.3	32
64	Perpetual change: autophagy, the endothelium, and response to vascular injury. Journal of Leukocyte Biology, 2017, 102, 221-235.	1.5	27
65	Intracellular HMGB1 as a novel tumor suppressor of pancreatic cancer. Cell Research, 2017, 27, 916-932.	5.7	103
66	Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational LoadÂTumor. Annals of Thoracic Surgery, 2017, 103, 1340-1349.	0.7	35
67	The NLRP3 inflammasome and bruton's tyrosine kinase in platelets co-regulate platelet activation, aggregation, and inÂvitro thrombus formation. Biochemical and Biophysical Research Communications, 2017, 483, 230-236.	1.0	74
68	Inhibition of Aurora Kinase A Induces Necroptosis inÂPancreaticÂCarcinoma. Gastroenterology, 2017, 153, 1429-1443.e5.	0.6	137
69	The Tumor Suppressor p53 Limits Ferroptosis by Blocking DPP4 Activity. Cell Reports, 2017, 20, 1692-1704.	2.9	608
70	Bortezomib Treatment Sensitizes Oncolytic HSV-1â€"Treated Tumors to NK Cell Immunotherapy. Clinical Cancer Research, 2016, 22, 5265-5276.	3.2	65
71	Until Death Do Us Part: Necrosis and Oxidation Promote the Tumor Microenvironment. Transfusion Medicine and Hemotherapy, 2016, 43, 120-132.	0.7	26
72	5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers. , 2016, 4, 65.		100

#	Article	IF	Citations
73	Identification of baicalein as a ferroptosis inhibitor by natural product library screening. Biochemical and Biophysical Research Communications, 2016, 473, 775-780.	1.0	174
74	The Receptor for Advanced Glycation End Products Activates the AIM2 Inflammasome in Acute Pancreatitis. Journal of Immunology, 2016, 196, 4331-4337.	0.4	50
75	IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Neuro-Oncology, 2016, 18, 1402-1412.	0.6	126
76	Platelet-derived high-mobility group box 1 promotes recruitment and suppresses apoptosis of monocytes. Biochemical and Biophysical Research Communications, 2016, 478, 143-148.	1.0	45
77	Autophagy promotes ferroptosis by degradation of ferritin. Autophagy, 2016, 12, 1425-1428.	4.3	1,318
78	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
79	Novel chemokine-like activities of histones in tumor metastasis. Oncotarget, 2016, 7, 61728-61740.	0.8	13
80	Consensus nomenclature for CD8⁺T cell phenotypes in cancer. OncoImmunology, 2015, 4, e998538.	2.1	119
81	The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Molecular and Cellular Oncology, 2015, 2, e1054549.	0.3	301
82	High-Mobility Group Box 1 Promotes Hepatocellular Carcinoma Progression through miR-21â€“Mediated Matrix Metalloproteinase Activity. Cancer Research, 2015, 75, 1645-1656.	0.4	80
83	Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9. Journal of Hepatology, 2015, 63, 114-121.	1.8	189
84	Parkinson Disease and Malignant Disease. JAMA Oncology, 2015, 1, 641.	3.4	2
85	Safety and Biologic Response of Pre-operative Autophagy Inhibition in Combination with Gemcitabine in Patients with Pancreatic Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 4402-4410.	0.7	187
86	Nuclear DAMP complex-mediated RAGE-dependent macrophage cellÂdeath. Biochemical and Biophysical Research Communications, 2015, 458, 650-655.	1.0	24
87	DAMPs, ageing, and cancer: The â€˜DAMP Hypothesisâ€™. Ageing Research Reviews, 2015, 24, 3-16.	5.0	117
88	Cytosolic HMGB1 controls the cellular autophagy/apoptosis checkpoint during inflammation. Journal of Clinical Investigation, 2015, 125, 1098-1110.	3.9	173
89	Activated Natural Killer Cells. , 2015, , 1-5.		0
90	Activated Natural Killer Cells. , 2015, , 26-30.		0

#	Article	IF	Citations
91	Clearance Kinetics and Matrix Binding Partners of the Receptor for Advanced Glycation End Products. PLoS ONE, 2014, 9, e88259.	1.1	16
92	Recombinant Human Interferon Alpha 2b Prevents and Reverses Experimental Pulmonary Hypertension. PLoS ONE, 2014, 9, e96720.	1.1	16
93	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	0.8	395
94	High Mobility Group Box 1 (HMGB1) Phenotypic Role Revealed with Stress. Molecular Medicine, 2014, 20, 359-362.	1.9	37
95	Cell Death and DAMPs in Acute Pancreatitis. Molecular Medicine, 2014, 20, 466-477.	1.9	119
96	IB-03 * IDH MUTANT GLIOMAS ARE RESISTANT TO NATURAL KILLER CELL-MEDIATED CYTOLYSIS. Neuro-Oncology, 2014, 16, v107-v107.	0.6	0
97	Intracellular Hmgb1 Inhibits Inflammatory Nucleosome Release and Limits Acute Pancreatitis in Mice. Gastroenterology, 2014, 146, 1097-1107.e8.	0.6	200
98	Progress in tuberculosis vaccine development and host-directed therapiesâ€"a state of the art review. Lancet Respiratory Medicine,the, 2014, 2, 301-320.	5.2	195
99	PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis. Nature Communications, 2014, 5, 4436.	5.8	346
100	HMGB1 in health and disease. Molecular Aspects of Medicine, 2014, 40, 1-116.	2.7	763
101	Targeting Damage-Associated Molecular Pattern Molecules (DAMPs) and DAMP Receptors in Melanoma. Methods in Molecular Biology, 2014, 1102, 537-552.	0.4	17
102	MÃ©nage Ã Trois in stress: DAMPs, redox and autophagy. Seminars in Cancer Biology, 2013, 23, 380-390.	4.3	43
103	The Receptor for Advanced Glycation End Products Promotes Pancreatic Carcinogenesis and Accumulation of Myeloid-Derived Suppressor Cells. Journal of Immunology, 2013, 190, 1372-1379.	0.4	47
104	Autophagy is required for IL-2-mediated fibroblast growth. Experimental Cell Research, 2013, 319, 556-565.	1.2	34
105	DAMPs and autophagy. Autophagy, 2013, 9, 451-458.	4.3	118
106	Autophagy and the Tumor Microenvironment. , 2013, , 167-189.		0
107	HMGB1 in Cancer: Good, Bad, or Both?. Clinical Cancer Research, 2013, 19, 4046-4057.	3.2	399
108	HMGB1: The Central Cytokine for All Lymphoid Cells. Frontiers in Immunology, 2013, 4, 68.	2.2	137

#	Article	IF	Citations
109	Inhibiting Autophagy. Cancer Journal (Sudbury, Mass), 2013, 19, 341-347.	1.0	29
110	PanIN-Specific Regulation of Wnt Signaling by HIF2Î± during Early Pancreatic Tumorigenesis. Cancer Research, 2013, 73, 4781-4790.	0.4	40
111	Sweating the Small Stuff. Pancreas, 2013, 42, 740-759.	0.5	28
112	The myeloid response to pancreatic carcinogenesis is regulated by the receptor for advanced glycation end-products. OncoImmunology, 2013, 2, e24184.	2.1	8
113	Signaling of High Mobility Group Box 1 (HMGB1) through Toll-like Receptor 4 in Macrophages Requires CD14. Molecular Medicine, 2013, 19, 88-98.	1.9	161
114	Tumor immunotherapy. , 2013, , 935-945.		0
115	Life after death: targeting high mobility group box 1 in emergent cancer therapies. American Journal of Cancer Research, 2013, 3, 1-20.	1.4	50
116	The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 7031-7036.	3.3	139
117	Pancreatic Cancer Is Not Noble. Journal of Innate Immunity, 2012, 4, 4-5.	1.8	7
118	<scp>PAMP</scp>s and <scp>DAMP</scp>s: signal 0s that spur autophagy and immunity. Immunological Reviews, 2012, 249, 158-175.	2.8	899
119	Blocking the interleukin 2 (IL2)-induced systemic autophagic syndrome promotes profound antitumor effects and limits toxicity. Autophagy, 2012, 8, 1264-1266.	4.3	28
120	Tumor immunity times out: TIM-3 and HMGB1. Nature Immunology, 2012, 13, 808-810.	7.0	96
121	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	4.3	3,122
122	AGER/RAGE-mediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathway. Autophagy, 2012, 8, 989-991.	4.3	82
123	Tumor-Cell Death, Autophagy, and Immunity. New England Journal of Medicine, 2012, 366, 1156-1158.	13.9	66
124	Damage Associated Molecular Pattern Molecule-Induced microRNAs (DAMPmiRs) in Human Peripheral Blood Mononuclear Cells. PLoS ONE, 2012, 7, e38899.	1.1	35
125	A Janus Tale of Two Active High Mobility Group Box 1 (HMGB1) Redox States. Molecular Medicine, 2012, 18, 1360-1362.	1.9	91
126	Inhibiting Systemic Autophagy during Interleukin 2 Immunotherapy Promotes Long-term Tumor Regression. Cancer Research, 2012, 72, 2791-2801.	0.4	133

#	Article	IF	Citations
127	Cell-Mediated Autophagy Promotes Cancer Cell Survival. Cancer Research, 2012, 72, 2970-2979.	0.4	122
128	p53/HMGB1 Complexes Regulate Autophagy and Apoptosis. Cancer Research, 2012, 72, 1996-2005.	0.4	220
129	RAGE regulates autophagy and apoptosis following oxidative injury. Autophagy, 2011, 7, 442-444.	4.3	71
130	High-Mobility Group Box 1 Is Essential for Mitochondrial Quality Control. Cell Metabolism, 2011, 13, 701-711.	7.2	266
131	Principles and Current Strategies for Targeting Autophagy for Cancer Treatment. Clinical Cancer Research, 2011, 17, 654-666.	3.2	789
132	High Mobility Group Box 1 (HMGB1) Activates an Autophagic Response to Oxidative Stress. Antioxidants and Redox Signaling, 2011, 15, 2185-2195.	2.5	118
133	High-Mobility Group Box 1, Oxidative Stress, and Disease. Antioxidants and Redox Signaling, 2011, 14, 1315-1335.	2.5	420
134	Metabolic regulation by HMGB1-mediated autophagy and mitophagy. Autophagy, 2011, 7, 1256-1258.	4.3	102
135	The Receptor for Advanced Glycation End-Products (RAGE) Protects Pancreatic Tumor Cells Against Oxidative Injury. Antioxidants and Redox Signaling, 2011, 15, 2175-2184.	2.5	76
136	Activated Natural Killer Cells. , 2011, , 19-23.		0
137	Biological activities of cytokine-neutralizing hyaluronic acid-antibody conjugates. Wound Repair and Regeneration, 2010, 18, 302-310.	1.5	16
138	Cancer and Inflammation: Promise for Biologic Therapy. Journal of Immunotherapy, 2010, 33, 335-351.	1.2	293
139	Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 12611-12616.	3.3	234
140	Zinc in innate and adaptive tumor immunity. Journal of Translational Medicine, 2010, 8, 118.	1.8	129
141	High-mobility group box 1 and cancer. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2010, 1799, 131-140.	0.9	442
142	Endogenous HMGB1 regulates autophagy. Journal of Cell Biology, 2010, 190, 881-892.	2.3	819
143	Quercetin Prevents LPS-Induced High-Mobility Group Box 1 Release and Proinflammatory Function. American Journal of Respiratory Cell and Molecular Biology, 2009, 41, 651-660.	1.4	106
144	Receptor-mediated signalling in plants: molecular patterns and programmes. Journal of Experimental Botany, 2009, 60, 3645-3654.	2.4	163

#	Article	IF	Citations
145	Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis. Journal of Leukocyte Biology, 2009, 86, 633-643.	1.5	149
146	Ethyl pyruvate administration inhibits hepatic tumor growth. Journal of Leukocyte Biology, 2009, 86, 599-607.	1.5	59
147	The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma. Medical Oncology, 2009, 26, 3-12.	1.2	17
148	Pharmacologic Administration of Interleukinâ€2. Annals of the New York Academy of Sciences, 2009, 1182, 14-27.	1.8	26
149	RAGE (Receptor for Advanced Glycation Endproducts), RAGE Ligands, and their role in Cancer and Inflammation. Journal of Translational Medicine, 2009, 7, 17.	1.8	491
150	Autophagy inhibition in combination cancer treatment. Current Opinion in Investigational Drugs, 2009, 10, 1269-79.	2.3	127
151	A nexus of science and clinical immunology: The Federation of Clinical Immunology Societies and the FOCIS Centers of Excellence. Clinical Immunology, 2008, 127, 119-120.	1.4	1
152	Pivotal Advance: Inhibition of HMGB1 nuclear translocation as a mechanism for the anti-rheumatic effects of gold sodium thiomalate. Journal of Leukocyte Biology, 2008, 83, 31-38.	1.5	45
153	Tumor immunology and immunotherapy. , 2008, , 1181-1195.		0
154	Not just nuclear proteins: 'novel' autophagy cancer treatment targets - p53 and HMGB1. Current Opinion in Investigational Drugs, 2008, 9, 1259-63.	2.3	14
155	Cytolytic cells induce HMGB1 release from melanoma cell lines. Journal of Leukocyte Biology, 2007, 81, 75-83.	1.5	81
156	Increasing numbers of hepatic dendritic cells promote HMGB1-mediated ischemia-reperfusion injury. Journal of Leukocyte Biology, 2007, 81, 119-128.	1.5	107
157	Report on the ISBTC Mini-symposium on Biologic Effects of Targeted Therapeutics. Journal of Immunotherapy, 2007, 30, 577-590.	1.2	2
158	Interleukin-10 (IL-10). , 2007, , 165-179.		0
159	Systemic inflammation and remote organ injury following trauma require HMGB1. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2007, 293, R1538-R1544.	0.9	199
160	High Mobility Group Box I (HMGB1) Release From Tumor Cells After Treatment: Implications for Development of Targeted Chemoimmunotherapy. Journal of Immunotherapy, 2007, 30, 596-606.	1.2	109
161	Eosinophilic Granulocytes and Damage-associated Molecular Pattern Molecules (DAMPs). Journal of Immunotherapy, 2007, 30, 16-28.	1.2	152
162	Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends in Immunology, 2007, 28, 429-436.	2.9	534

#	Article	IF	Citations
163	Masquerader: High Mobility Group Box-1 and Cancer. Clinical Cancer Research, 2007, 13, 2836-2848.	3.2	335
164	The grateful dead: damageâ€associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunological Reviews, 2007, 220, 60-81.	2.8	565
165	Damage associated molecular pattern molecules. Clinical Immunology, 2007, 124, 1-4.	1.4	100
166	Rapid flow cytometric measurement of cytokine-induced phosphorylation pathways [CIPP] in human peripheral blood leukocytes. Clinical Immunology, 2006, 121, 215-226.	1.4	32
167	Successful simultaneous measurement of cell membrane and cytokine induced phosphorylation pathways [CIPP] in human peripheral blood mononuclear cells. Journal of Immunological Methods, 2006, 313, 48-60.	0.6	12
168	High Mobility Group B1 Protein Suppresses the Human Plasmacytoid Dendritic Cell Response to TLR9 Agonists. Journal of Immunology, 2006, 177, 8701-8707.	0.4	59
169	Cutting Edge: High-Mobility Group Box 1 Preconditioning Protects against Liver Ischemia-Reperfusion Injury. Journal of Immunology, 2006, 176, 7154-7158.	0.4	113
170	Addicted to Death. Journal of Immunotherapy, 2005, 28, 1-9.	1.2	140
171	High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nature Reviews Immunology, 2005, 5, 331-342.	10.6	2,218
172	Cytolytic Assays. , 2005, , 343-349.		6
173	The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion. Journal of Experimental Medicine, 2005, 201, 1135-1143.	4.2	1,634
174	The Enhanced Tumor Selectivity of an Oncolytic Vaccinia Lacking the Host Range and Antiapoptosis Genes SPI-1 and SPI-2. Cancer Research, 2005, 65, 9991-9998.	0.4	111
175	Natural killerâ€"dendritic cell cross-talk in cancer immunotherapy. Expert Opinion on Biological Therapy, 2005, 5, 1303-1315.	1.4	99
176	Monocytes promote natural killer cell interferon gamma production in response to the endogenous danger signal HMGB1. Molecular Immunology, 2005, 42, 433-444.	1.0	98
177	Imaging Cytometry: High Content Screening for Large-Scale Cell Research. , 2005, , 660-665.		0
178	Inflammation and necrosis promote tumour growth. Nature Reviews Immunology, 2004, 4, 641-648.	10.6	592
179	A primer on cancer immunology and immunotherapy. Cancer Immunology, Immunotherapy, 2004, 53, 135-138.	2.0	8
180	Identifying biomarkers and surrogates of tumors (cancer biometrics): correlation with immunotherapies and immune cells. Cancer Immunology, Immunotherapy, 2004, 53, 256-261.	2.0	15

#	Article	IF	Citations
181	Cancer as a chronic inflammatory disease: role of immunotherapy. , 2004, , 21-51.		3
182	Dying dangerously: Necrotic cell death and chronic inflammation promote tumor growth. Discovery Medicine, 2004, 4, 448-56.	0.5	4
183	The critical need for cancer biometrics: quantitative, reproducible measures of cancer to define response to therapy. Current Opinion in Investigational Drugs, 2003, 4, 649-51.	2.3	1
184	Dealing with death: HMGB1 as a novel target for cancer therapy. Current Opinion in Investigational Drugs, 2003, 4, 1405-9.	2.3	47
185	Paucity of dendritic cells in pancreatic cancer. Surgery, 2002, 131, 135-138.	1.0	105
186	Dendritic Cells Pulsed With Apoptotic Squamous Cell Carcinoma Have Anti-Tumor Effects When Combined With Interleukin-2. Laryngoscope, 2001, 111, 1472-1478.	1.1	15
187	Potent antitumor effects of intra-arterial injection of fibroblasts genetically engineered to express IL-12 in liver metastasis model of rat: No additional benefit of using retroviral producer cell. Cancer Gene Therapy, 2001, 8, 17-22.	2.2	9
188	Characterization and transduction of a retroviral vector encoding human interleukin-4 and herpes simplex virus-thymidine kinase for glioma tumor vaccine therapy. Cancer Gene Therapy, 2000, 7, 486-494.	2.2	13
189	Dendritic Cell/Peptide Cancer Vaccines: Clinical Responsiveness and Epitope Spreading. Immunological Investigations, 2000, 29, 121-125.	1.0	61
190	Recent Advances in Melanoma Staging and Therapy. Annals of Surgical Oncology, 1999, 6, 467-475.	0.7	64
191	High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993. Journal of Clinical Oncology, 1999, 17, 2105-2105.	0.8	1,810
192	Interleukin-12 Gene Therapy Prevents Establishment of SCC VII Squamous Cell Carcinomas, Inhibits Tumor Growth, and Elicits Long-term Antitumor Immunity in Syngeneic C3H Mice. Laryngoscope, 1998, 108, 261-268.	1.1	32
193	Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms. , 1998, 78, 196-201.		95
194	Distant skin and soft tissue metastases from sarcomas. , 1998, 69, 94-98.		31
195	Distant skin and soft tissue metastases from sarcomas. Journal of Surgical Oncology, 1998, 69, 94-98.	0.8	3
196	Tumor Recognition by the Cellular Immune System: New Aspects of Tumor Immunology. International Reviews of Immunology, 1997, 14, 97-132.	1.5	7
197	Introduction. Annals of the New York Academy of Sciences, 1996, 795, xiii-xix.	1.8	5
198	Murine Models of Cancer Cytokine Gene Therapy Using Interleukin-12. Annals of the New York Academy of Sciences, 1996, 795, 275-283.	1.8	34

#	Article	IF	Citations
199	Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes. European Journal of Immunology, 1996, 26, 2613-2623.	1.6	6
200	Clinical Trial to Assess the Safety, Feasibility, and Efficacy of Transferring a Potentially Anti-Arthritic Cytokine Gene to Human Joints with Rheumatoid Arthritis. University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Human Gene Therapy, 1996, 7, 1261-1280.	1.4	254
201	Host immune response in renal cell cancer: Interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. Cancer Immunology, Immunotherapy, 1995, 41, 111-121.	2.0	6
202	Retroviral Vectors for Use in Human Gene Therapy for Cancer, Gaucher Disease, and Arthritis. Annals of the New York Academy of Sciences, 1994, 716, 72-89.	1.8	39
203	Usage of T-cell receptor VÎ² chain genes in fresh and cultured tumor-infiltrating lymphocytes from human melanoma. International Journal of Cancer, 1993, 54, 383-390.	2.3	38
204	In company. Nature, 1991, 353, 467-468.	13.7	1
205	Healing arts. Nature, 1990, 347, 587-588.	13.7	0
206	High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. , 0, .		1